PAI-039 - CAS# 393105-53-8 0287 The subcutaneous tumor growth of

The subcutaneous tumor growth of both T24 and HeLa cell xenografts treated with PAI-039 is markedly reduced compared with untreated controls

Pretreatment of cancer cells with a KDM5-specific inhibitor results in the ablation of a subpopulation of cancer cells that can serve as the founders for therapeutic relapse

Chemical Name: Compound Library of Histone Methyltransferase

It inhibits phosphorylation of the mTORC1 substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate AKT in diverse cancer models in vitro and in vivo

the combination of Dasatinib and GNF-2 overcame resistance of BCR/ABL-T315I in all models used in a synergistic manner

PAI-039 - CAS# 393105-53-8 0287 The subcutaneous tumor growth ofPAI 039, CAS No. 393105 53 8, is a novel plasminogen activator inhibitor 1 (PAI 1) inhibitor. The pharmacokinetic profile of PAI 039 indicated an oral bioavailability of 43 + 15. 3% and a plasma half life of 6. 2 + 1. 3 h. PAI 039 is an orally active prothrombolytic drug that inhibits PAI 1 and accelerates fibrinolysis while maintaining normal coagulation in a model of coronary occlusion . PAI 039 exerts antithrombotic efficacy in rat models of